Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
HuVePharma from Antwerpen, company number BE0875283062, closed financial year 2025 with a result of € 5.9 million after tax. For that financial year HuVePharma recorded revenue of € 127.1 million and equity of € 49.8 million. Compared with financial year 2024, the result moved from € 4.8 million to € 5.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.
€ 49.8 million
▲ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 5.9 million
▲ 23% vs 2024
Profit after tax over the fiscal year.
€ 4.6 million
▼ 21% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 45.3 million.
People and assets in 2025
102.2
▲ 20.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 16.9 million
▲ 41% vs 2024
€ 165,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 168,446
▲ 18% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 107,063
▼ 42% vs 2024
€ 79,206 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.
€ 47.2 million
▲ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 128 days on average.
€ 3.1 million
▲ 49% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 100,702,342 | € 100,297,083 | € 115,026,597 | € 127,095,181 | ▲ 10% |
| Profit after taxes | € 4,340,052 | € 4,288,792 | € 4,777,338 | € 5,890,253 | ▲ 23% |
| Equity | € 34,820,974 | € 39,109,766 | € 43,887,104 | € 49,777,357 | ▲ 13% |
| Total debts | € 46,301,346 | € 43,544,538 | € 53,653,181 | € 57,911,661 | ▲ 8% |
| Cash | € 4,654,847 | € 4,355,909 | € 5,797,695 | € 4,591,821 | ▼ 21% |
| Retained profit | € 30,320,974 | € 34,609,766 | € 39,387,104 | € 45,277,357 | ▲ 15% |
| Bank debt | € 138,068 | € 224,748 | € 185,302 | € 107,063 | ▼ 42% |
| Balance sheet total | € 81,122,320 | € 82,654,304 | € 97,540,285 | € 107,689,018 | ▲ 10% |
| Employees (FTE) | 79.3 | 81 | 82 | 102.2 | ▲ 20.2 |
Key figures of HuVePharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to HuVePharma?
What happened at HuVePharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- SDL Management BV stepped down as director. NBB
- Kiril DOMUSCHIEV stepped down as director. NBB
- Eddy PIRON stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 5.9 million (▲ 23% vs 2024). Source: NBB ↗
- SDL Management BV became a director. NBB
- Kiril DOMUSCHIEV became a director. NBB
- Eddy PIRON became a director. NBB
- New establishment in Antwerpen. KBO
In short
From € 4.3 million profit in 2022 to € 5.9 million profit in 2025.
Paid € 6.5 million in corporate taxes since 2022.
Best year ever: 2025, with € 5.9 million profit.
Pays suppliers within 128 days on average.
A new publication or filing at HuVePharma? We notify you, reason included.
Follow HuVePharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 100% of Huvepharma Netherlands BV itself.
Directors
According to the 2025 annual accounts
Kiril DOMUSCHIEV
Chairman of the board
since 2017 · until 2029
since 2017 · until 2029
Director · represented by Sven Verbraeken
since 2024 · until 2030
Establishments
Establishment units
Physical locations of this company
Uitbreidingstraat 80
2600 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0875.283.062
- VAT number
- BE 0875.283.062
- Registered office
- Uitbreidingstraat 80, 2600 Antwerpen
- Names & denominations
- HuVePharma
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 July 2005
- Peppol
- Active · Active since 28 Aug 2025
- Activities · NACE
Overige gespecialiseerde groothandel in voedingswaren
Groothandel in andere voedingsmiddelen, neg
Groothandel in akkerbouwproducten en veevoeders, algemeen assortiment
Groothandel in granen, zaden en diervoeders